- Alpha Cognition (ACOG) has closed its public offering for aggregate gross proceeds of $14.4 million
- Alpha issued 9,602,500 units at a price of $1.50 per unit
- The public offering was conducted by a group of agents led by Raymond James Ltd. and iA Private Wealth Inc.
- Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases like Alzheimer’s and Dementia
- Alpha Cognition Inc. is up 2.19 per cent today, trading at C$1.40 as of 1:01 p.m. ET
Alpha Cognition (ACOG) has closed its public offering for aggregate gross proceeds of $14.4 million.
Alpha issued 9,602,500 units at a price of $1.50 per unit.
The public offering was conducted by a group of agents led by Raymond James Ltd. and iA Private Wealth Inc.
Net proceeds will be used for clinical development and marketing of two of its pre-clinical products to help people dealing with neurodegenerative diseases.
The securities will not be registered under the U.S. Securities Act, and will not be offered or sold in the United States.
Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases like Alzheimer’s and Dementia.
Alpha Cognition Inc. is up 2.19 per cent today, trading at C$1.40 as of 1:01 p.m. ET.